骨肉瘤的诊断及生物学治疗进展
Diagnosis and Progress in Biological Treatment of Osteosarcoma

DOI: 10.12677/HJBM.2019.93017, PP. 114-120

Keywords: 骨肉瘤，诊断，免疫治疗，PD-1，CAR-T
Osteosarcoma, Diagnosis, Immunotherapy, PD-1, CAR-T

Full-Text   Cite this paper   Add to My Lib

Abstract:

骨肉瘤是严重威胁患者健康和生命的一种原发性恶性肿瘤。随着医疗科学技术的发展，治疗方法日益多样，近几年多提倡手术治疗与化疗结合的综合性治疗方案，这能将患者五年生存率提高至60%~70%。为了提高患者生存质量，延长患者生存时间，骨肉瘤治疗的关键在于对骨肉瘤的早发现，早治疗。本文就目前骨肉瘤的诊断方式和近年来骨肉瘤在免疫信号通路、血管靶向、修饰T细胞、等方面取得的研究进展进行综述。
Osteosarcoma is a primary malignant tumor that seriously threatens the health and life of patients. With the development of medical science and technology, treatment methods are becoming more and more diverse. In recent years, more comprehensive treatment schemes combining surgical treatment and chemotherapy are advocated, which can improve the five-year survival rate of patients to 60% - 70%. In order to improve the quality of life and prolong the survival time of patients, the key to the treatment of osteosarcoma lies in the early detection and treatment of osteosarcoma. This article reviews the current diagnostic methods of osteosarcoma and recent advances in immune signaling pathways, vascular targeting, modified T cells and other aspects of osteosarcoma.

References

[1]	Isakoff, M.S., Bielack, S.S., Meltzer, P., et al. (2015) Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. Journal of Clinical Oncology, 33, 3029-3035. https://doi.org/10.1200/JCO.2014.59.4895
[2]	王显阳, 常君丽, 施杞, 等. 骨肉瘤相关信号通路的研究进展[J]. 中国癌症防治杂志, 2015, 7(1): 52-55.
[3]	Fidler, M.M., Frobisher, C., Guha, J., et al. (2015) Long-Term Adverse Outcomes in Survivors of Childhood Bone Sarcoma: The British Childhood Cancer Survivor Study. British Journal of Cancer, 112, 1857-1865. https://doi.org/10.1038/bjc.2015.159
[4]	Allson, D.C., Carney, S.C., Ahlmann, E.R., et al. (2012) A Me-ta-Analysis of Osteosarcoma Outcomes in the Modern Medical Era. Sarcoma, 2012, Article ID: 704872. https://doi.org/10.1155/2012/704872
[5]	Wu, P.K., Chen, W.M., Chen, C.F., et al. (2000) Primary Osteogenic Sarcoma with Pulmonary Metastasis: Clinical Results and Prognostic Factors in 91 Patients. Japanese Journal of Clinical Oncology, 30, 514-522. https://doi.org/10.1093/jjco/hyp057
[6]	李汉忠, 张玉石, 郑国洋. 肿瘤免疫治疗: 回顾与展望[J]. 协和医学杂志, 2018, 9(4): 289-294.
[7]	黄志鹏, 宋科官. 骨肉瘤的诊断及治疗进展[J]. 国际骨科学杂志, 2018, 39(3): 150-153.
[8]	严海林. 骨肉瘤流行病学研究及术前风险评分模型的构建[D]: [博士学位论文]. 杭州: 浙江大学, 2017.
[9]	周四清, 毋凡, 王继峰, 等. 骨肉瘤的X线、CT、MRI影像对比诊断[J]. 实用医学杂志, 2009, 25(20): 3467-3468.
[10]	王玲, 王燕, 冯琛, 潘禹铮, 张英泽. 骨肉瘤免疫治疗的研究进展[J]. 中华老年骨科与康复电子杂志, 2017, 3(6): 381-384.
[11]	郑冠群, 赵福友, 吴穷, 杨燕. PD-1及其配体在骨肉瘤免疫治疗中的研究进展[J]. 中华全科医学, 2016, 14(9): 1560-1562.
[12]	孙保国, 陈泽雄, 张诗军, 刘泳冬, 黄红中, 尹丽荣. 复方中药对裸鼠肝癌模型PTEN蛋白表达的影响[J]. 中国中药杂志, 2007(11): 1057-1060.
[13]	Zheng, W.J., Xiao, H., Liu, H., et al. (2014) Expression of Programmed Death 1 Is Correlated with Progression of Osteosarcoma. APMIS, 123, 102-107. https://doi.org/10.1111/apm.12311
[14]	Simeone, E. and Ascierto, P.A. (2012) Immunomodulating Antibodies in the Treatment of Metastatic Melanoma: The Experience with Anti-CTLA-4, Anti-CD137 and Anti-PD1. Journal of Immunotoxicology, 9, 241-247. https://doi.org/10.3109/1547691X.2012.678021
[15]	Lussier, D.M., Johnson, J.T., Hingorani, P., et al. (2015) Combination Immunotherapy with ɑ-CTLA-4 and ɑ-PD-L1 Antibody Blockade Prevents Immune Escape and Leads to Complete Control of Metastatic Osteosarcoma. Journal for Immunotherapy of Cancer, 3, 21. https://doi.org/10.1186/s40425-015-0067-z
[16]	Gobin, B., Battaglia, S., Lanel, R., et al. (2014) NVPBEZ235, a Dual PI3K/mTOR Inhibitor, Inhibits Osteosarcoma Cell Proliferation and Tumor Development in Vivo with an Improved Survival Rate. Cancer Letters, 344, 291-298. https://doi.org/10.1016/j.canlet.2013.11.017
[17]	郑杰, 宋来君. 过表达HIF-1α和VEGF蛋白与垂体腺瘤侵袭行为的关系[J]. 现代肿瘤医学, 2018, 26(12): 1845-1848.
[18]	李桃英, 高珊珊, 刘鹏森, 朱宝菊. ER、VEGF、TGF-β1在增生期子宫内膜良恶性肿瘤中的表达及其相关性研究[J]. 实用癌症杂志, 2018, 33(3): 349-352.
[19]	谭胜, 王国祥. 外周血内VEGF水平对食管癌患者放化疗效果分析[J]. 北华大学学报(自然科学版), 2018, 19(1): 56-59.
[20]	Yu, X.W., Wu, T.Y., Yi, X., et al. (2014) Prognostic Significance of VEGF Expression in Osteosarcoma: A Meta-Analysis. Tumour Biology, 35, 155-160. https://doi.org/10.1007/s13277-013-1019-1
[21]	王东, 仲召阳, 李增鹏, 张沁宏, 何怡, 卿毅. 骨肉瘤VEGF表达及VEGF抗体抑制血管生成的实验研究[J]. 重庆医学, 2006(15): 1369-1372.
[22]	李龙. 抗血管内皮生长因子受体药物治疗晚期胃癌的Meta分析[D]: [硕士学位论文]. 兰州: 兰州大学, 2017.
[23]	Hu, Y., Wu, Z., Luo, Y., et al. (2017) Potent Anti-Leukemia Activities of Chimeric Antigen Re-ceptor-Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia. Clinical Cancer Research, 23, 3297-3306. https://doi.org/10.1158/1078-0432.CCR-16-1799
[24]	Locke, F.L., Neelapu, S.S., Bartlett, N.L., et al. (2017) Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Molecular Therapy, 25, 285-295. https://doi.org/10.1016/j.ymthe.2016.10.020
[25]	Gardner, R.A., Finney, O., Annesley, C., et al. (2017) In-tent-to-Treat Leukemia Remission by CD19 CAR T Cells of Defined Formulation and Dose in Children and Young Adults. Blood, 129, 3322-3331.
[26]	FDA (2017) FDA Approves CAR-T Cell Therapy to Treat Adults with Certain Types of Large B-Cell Lymphoma. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm581216.htm
[27]	Huang, X., Park, H., Greene, J., et al. (2015) IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas. PLoS ONE, 10, e0133152. https://doi.org/10.1371/journal.pone.0133152
[28]	Liu, T., Ma, Q., Zhang, Y., et al. (2015) Interleukin-11 Receptor α Is Overexpressed in Human Osteosarcoma, and Nearinfrared-Labeled IL-11R α Imaging Agent Could Detect Osteosarcoma in Mouse Tumor Xenografts. Tumor Biology, 36, 2369-2375. https://doi.org/10.1007/s13277-014-2844-6
[29]	Suzuki, M. and Cheung, N.K. (2015) Disialoganglioside GD2 as a Therapeutic Target for Human Diseases. Expert Opinion on Therapeutic Targets, 19, 349-362. https://doi.org/10.1517/14728222.2014.986459
[30]	Bozzi, F., Tamborini, E., Negri, T., et al. (2007) Evidence for Activation of KIT, PDGFR Alpha, and PDGFR Beta Receptors in the Ewing Sarcoma Family of Tumors. Cancer, 109, 1638-1645. https://doi.org/10.1002/cncr.22587
[31]	Takagi, S., Takemoto, A., Takami, M., et al. (2014) Platelets Promote Osteosarcoma Cell Growth through Activation of the Platelet-Derived Growth Factor Receptor Akt Signaling Axis. Cancer Science, 105, 983-998. https://doi.org/10.1111/cas.12464

Full-Text